Is Telavancin Effective in the Treatment of Bacteremia, Endocarditis?

Most patients received telavancin as a second-line therapy at a median daily dose of 8.7mg/kg or 743.6mg
Most patients received telavancin as a second-line therapy at a median daily dose of 8.7mg/kg or 743.6mg

This article is written live from ID Week 2017 Annual Meeting in San Diego, CA. MPR will be reporting news on the latest findings from leading experts in infectious diseases. Check back for more news from IDWeek 2017.


SAN DIEGO—Treatment with telavancin produced positive clinical outcomes in patients with bacteremia or endocarditis, according to real-world data presented at IDWeek 2017 in San Diego, CA.

"[Staphylococcus] aureus bacteremia treatment remains a major challenge and more effective therapies are needed," said lead author Joseph Reilly, PharmD, CGP. Telavancin is a lipoglycopeptide antibacterial agent FDA-approved for the treatment of complicated skin and skin structure infections due to susceptible Gram-positive bacteria. It is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia due to S. aureus. 

To investigate the efficacy of telavancin in the treatment of bacteremia and infective endocarditis, the study authors looked at data from the Telavancin Observational Use Registry (TOUR), which reports on outcomes of patients treated with telavancin in clinical practice.

Out of the over 1,000 patients for whom data was available for analysis, 148 patients were treated for bacteremia and/or infective endocarditis. In this group, methicillin-resistant Staphylococcus aureus (MRSA) was the most commonly isolated pathogen (n=84). Most patients received telavancin as a second-line therapy (mainly in an inpatient setting) at a median daily dose of 8.7mg/kg or 743.6mg and for a median duration of 9 days. 

Among patients who had a response assessment at the end of telavancin treatment, 74.2% (98/132) had a positive clinical outcome (cured or improved to step-down oral therapy); 10.6% of patients failed therapy and 15.2% had missing or undocumented outcomes. With regard to adverse events, 23 patients reported at least 1 treatment-emergent adverse event; 18 experienced serious adverse events, while 15 had an adverse event that led to treatment discontinuation.

"These preliminary, real-world data suggest that once-daily [telavancin] may represent an alternative treatment option for patients with S. aureus bacteremia or endocarditis," the authors concluded. 

For continuous endocrine news coverage from the IDWeek 2017, check back to MPR's IDWeek page for the latest updates.

Reference:

Reilly, J; Jacobs, M; Lat, A; Osmukhina, A; Castaneda-Ruiz, B. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary results from the Telavancin Observational Use Registry (TOUR).  Poster presented at IDWeek; October 4–8, 2017; San Diego, CA. http://www.idweek.org.